No, Do Not Stop Rosuvastatin and Ezetimibe When Starting Repatha
When initiating evolocumab (Repatha), you should continue both rosuvastatin and ezetimibe—PCSK9 inhibitors are designed to be added on top of maximally tolerated statin therapy with or without ezetimibe, not to replace them. This combination approach provides the most substantial LDL-C reduction and cardiovascular benefit.
The Evidence-Based Rationale
Guidelines Universally Recommend Combination Therapy
All major guidelines from 2019-2022 consistently specify that PCSK9 inhibitors should be added to existing lipid-lowering therapy, not substituted for it 1:
European Society of Cardiology/European Atherosclerosis Society (2019): For very high-risk patients who don't achieve LDL-C goals on maximum tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level A for secondary prevention) 1
Canadian Cardiovascular Society (2021): Add ezetimibe to maximally tolerated statin when LDL-C remains ≥70 mg/dL (1.8 mmol/L). If LDL-C on statin plus ezetimibe remains ≥100 mg/dL (2.6 mmol/L), adding a PCSK9 inhibitor is reasonable 1
American College of Cardiology (2022): PCSK9 inhibitors are used "in combination with nonstatin therapy" as adjunct to maximally tolerated statin 2
FDA Label Confirms Combination Use
The Repatha FDA label explicitly states evolocumab is indicated "as adjunct to diet, either alone or in combination with other lipid-lowering therapies" 3. Clinical trials demonstrating evolocumab's efficacy consistently used it on top of background statin therapy:
- In the TESLA trial (HoFH patients), all patients remained on statins (atorvastatin or rosuvastatin) and 92% continued ezetimibe while adding evolocumab 3
- The FOURIER trial showed a 20% reduction in cardiovascular death, MI, or stroke when evolocumab was added to statin therapy 4
Synergistic Lipid-Lowering Effect
The combination provides additive LDL-C reduction through complementary mechanisms 5:
- Rosuvastatin alone: ~33% LDL-C reduction
- Rosuvastatin + Ezetimibe: ~52% LDL-C reduction
- Rosuvastatin + Ezetimibe + Evolocumab: ~74% LDL-C reduction
This triple therapy achieves LDL-C reductions of 63-75% compared to baseline, with evolocumab contributing an additional 37-39% reduction beyond ezetimibe 6, 7.
Clinical Implementation Algorithm
Step 1: Verify the patient is on maximally tolerated statin therapy (rosuvastatin in this case)
Step 2: Confirm ezetimibe has been added and LDL-C remains above goal despite this combination
Step 3: Add evolocumab 140 mg subcutaneously every 2 weeks OR 420 mg monthly while continuing both rosuvastatin and ezetimibe 3
Step 4: Reassess LDL-C at weeks 10-12 to evaluate response
Common Pitfalls to Avoid
Do not discontinue statins or ezetimibe when starting evolocumab. This is a critical error that would:
- Eliminate the synergistic lipid-lowering effect
- Reduce overall LDL-C reduction by approximately 50%
- Diminish cardiovascular event reduction benefits
- Contradict all guideline recommendations and FDA labeling
The only scenario where you might use evolocumab without a statin is in patients with documented statin intolerance who cannot tolerate any statin dose 8, 9. Even then, ezetimibe should be continued if tolerated.
Safety Considerations
The combination of evolocumab with statins and ezetimibe has been extensively studied with favorable safety profiles 5, 6:
- Muscle-related adverse events occurred in only 20.7% of evolocumab-treated patients versus 28.8% with ezetimibe alone 8
- No increase in treatment-emergent adverse events beyond injection site reactions
- Safe even at very low LDL-C levels achieved with triple therapy 4
The evidence is unequivocal: maintain your patient on rosuvastatin and ezetimibe when initiating Repatha to maximize LDL-C reduction and cardiovascular protection.